Curaleaf Holdings (CURLF) Total Current Liabilities (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Total Current Liabilities of $294.3 million for Q4 2025, down 24.13% year-on-year from $387.9 million in Q4 2024, and down 24.13% on a QoQ basis from $387.9 million in Q4 2024.
Curaleaf Holdings (CURLF) Total Current Liabilities (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Total Current Liabilities for 7 consecutive years, with $294.3 million the latest figure, recorded in Q4 2025.
- Quarterly Total Current Liabilities fell 24.13% year-over-year to $294.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $294.3 million (down 24.13% YoY) and the FY2025 annual result came in at $294.3 million, down 24.13% from the prior year.
- Total Current Liabilities retreated to $294.3 million in Q4 2025 per CURLF's latest filing, from $387.9 million in the prior quarter.
- Over the last five years, Total Current Liabilities for CURLF reached as high as $436.8 billion in Q1 2022 and fell as low as $215.3 million in Q2 2021.
- A 5-year average of $29.5 billion and a median of $387.9 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 183454.65% — and 2024, when it sank 31.81%.
- Year by year, Total Current Liabilities stood at $316.2 million in 2021, then surged by 57.12% to $496.9 million in 2022, then slipped by 0.57% to $494.0 million in 2023, then dropped by 21.48% to $387.9 million in 2024, then dropped by 24.13% to $294.3 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $294.3 million, $387.9 million, and $379.3 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 294.31 Mn |
| Dec 31, 2024 | 387.93 Mn |
| Sep 30, 2024 | 379.26 Mn |
| Jun 30, 2024 | 392.51 Mn |
| Dec 31, 2023 | 494.03 Mn |
| Sep 30, 2023 | 556.21 Mn |
| Jun 30, 2023 | 515.88 Mn |
| Dec 31, 2022 | 496.87 Mn |
| Sep 30, 2022 | 436.92 Mn |
| Jun 30, 2022 | 382.65 Mn |
| Mar 31, 2022 | 436.81 Bn |
| Dec 31, 2021 | 316.24 Mn |
| Sep 30, 2021 | 335.21 Mn |
| Jun 30, 2021 | 215.35 Mn |
| Mar 31, 2021 | 237.97 Mn |
| Dec 31, 2020 | 220.13 Mn |
| Sep 30, 2020 | 177.15 Mn |
| Dec 31, 2019 | 106.26 Mn |